<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471848</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT: 2007-000902-55</org_study_id>
    <secondary_id>RATGAA07</secondary_id>
    <nct_id>NCT00471848</nct_id>
  </id_info>
  <brief_title>Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia</brief_title>
  <acronym>RATGAA07</acronym>
  <official_title>Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia and Comparison With Matched Historical Patients Treated With Horse ATG and Ciclosporin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Society for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Society for Blood and Marrow Transplantation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the tolerability and effectiveness of rabbit antithymocyte globulin (ATG,&#xD;
      Thymoglobuline) with ciclosporin in the first line treatment of patients with acquired severe&#xD;
      aplastic anaemia, and patients with non-severe aplastic anaemia and who are transfusion&#xD;
      dependent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traditionally horse antithymocyte globulin (ATG) has been the preferred animal source of ATG&#xD;
      as first line treatment for acquired aplastic anaemia (AA) patients who are ineligible for&#xD;
      bone marrow transplantation (BMT). For severe AA (SAA) the combination of ATG and Ciclosporin&#xD;
      (CSA) results in response in 60-75% of patients and the response is superior to using either&#xD;
      agent alone. The addition of granulocyte colony stimulating factor (G-CSF) to the combination&#xD;
      of ATG and CSA has so far shown no significant benefit in terms of response and survival, but&#xD;
      an European Group for Blood and Marrow Transplantation (EBMT) prospective study is currently&#xD;
      evaluating this further in a larger number of patients. For patients with non-severe aplastic&#xD;
      anaemia (NSAA) who are transfusion dependent, the combination of ATG and CSA was shown to be&#xD;
      superior to CSA alone in an EBMT prospective randomised study, with a higher response rate,&#xD;
      superior blood counts and improved disease free survival using the combination of ATG with&#xD;
      CSA.&#xD;
&#xD;
      There have been no phase II studies of rabbit ATG (Thymoglobuline®) in the treatment of AA as&#xD;
      first line therapy. Preliminary results from a small single centre study compared horse ATG&#xD;
      (ATGAM) with rabbit ATG (Fresenius) in children and showed response rates of 93% and 47%,&#xD;
      respectively, but it is likely that different preparations of rabbit ATG will vary in their&#xD;
      efficacy. Rabbit ATG is more commonly used for a second course following relapse or lack of&#xD;
      response to a first course of horse ATG. Rabbit ATG in combination with CSA and G-CSF was&#xD;
      used in patients with SAA who had failed to respond to a course of horse ATG with CSA and&#xD;
      G-CSF. Overall response (transfusion independence) was seen in 23/30 (77%) of patients after&#xD;
      a median of 95 days and complete response (neutrophils &gt; 2.0, haemoglobin &gt; 11, and platelets&#xD;
      &gt; 100) in 9/30 (30%). Rabbit ATG was well tolerated; no anaphylaxis or severe side effects&#xD;
      were reported. Another study of 43 patients treated with rabbit ATG and CSA following&#xD;
      non-response or relapse after horse ATG and CSA, showed 30% response rate among&#xD;
      non-responding patients and 65% response rate for relapsing patients.&#xD;
&#xD;
      Studies comparing the antibody specificities between Thymoglobuline® and Lymphoglobuline® are&#xD;
      in broad agreement, but (a) Lymphoglobuline® has fewer studies and those reported are older,&#xD;
      because the product is older and has been less extensively developed (b) antibodies against&#xD;
      certain epitopes are inconsistently present (c) not all antibody specificities have been&#xD;
      examined in some studies and (d) different methods of testing have been used. There is a view&#xD;
      that it is the immunogen and not the animal species which is most important in creating&#xD;
      differences between different ATGs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Response to Rabbit Antithymocyte Globuline (Thymoglobuline)</measure>
    <time_frame>at 6months</time_frame>
    <description>Complet Response (CR) defined as:&#xD;
Haemoglobin normal for age and gender, neutrophils &gt; 1.5 x 10E9/l, platelets &gt; 150 x 10E9/l.&#xD;
Partial Response (PR) defined as:&#xD;
transfusion independence (if previously dependent) or&#xD;
doubling or normalisation of at least one cell line or&#xD;
increase of baseline haemoglobin of &gt; 3 g/dl (if initially &lt;6) + neutrophils of &gt; 0.5 x 10E9/l + platelets of &gt; 20 x 10E9/l (if initially &lt; 20)&#xD;
No Response (MR) is defined as: worse or not meeting criteria above</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure Free and Overall Survival of Participants to Rabbit Antithymocyte Globuline (Thymoglobuline)</measure>
    <time_frame>at 2 years</time_frame>
    <description>Failure free survival is defined as a failure of the protocol: no achievement of response, relapse, disease progression requiring a second course of immune suppressive therapy (IST) or a stem cell transplant, death, or later clonal disorders such as PNH, MDS and AML.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antithymocyte globuline with cyclosporin in first line treatment of patients with acquired severe aplastic anaemia and patients with non-severe aplastic anaemia who are transfusion dependent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rabbit antithymocyte globulin</intervention_name>
    <description>1.5 vials/10kg daily for 5 days</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Thymoglobuline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must fulfil definition of aplastic anaemia:&#xD;
&#xD;
             There must be at least two of the following:&#xD;
&#xD;
               -  haemoglobin &lt; 10g/dl&#xD;
&#xD;
               -  platelet count &lt; 50 x 109/l&#xD;
&#xD;
               -  neutrophil count &lt; 1.5 x 109/l, and a hypocellular bone marrow on bone marrow&#xD;
                  biopsy&#xD;
&#xD;
             SAA as defined by a hypocellular bone marrow of &lt;25% cellularity and two of the&#xD;
             following:&#xD;
&#xD;
               -  neutrophil count &lt; 0.5 x 109/l&#xD;
&#xD;
               -  platelets &lt; 20 x 109/l&#xD;
&#xD;
               -  reticulocytes &lt; 20 x 109/l&#xD;
&#xD;
             NSAA as defined by a hypocellular bone marrow and cytopenia in at least two cell lines&#xD;
             and neutrophil count &gt; 0.5 x 109/l, and red cell and/or platelet transfusion&#xD;
             dependence&#xD;
&#xD;
          2. Have acquired aplastic anaemia&#xD;
&#xD;
          3. Time from diagnosis to study registration maximum 6 months&#xD;
&#xD;
          4. No prior treatment except for haemopoietic growth factors given for no more than four&#xD;
             weeks, and androgens&#xD;
&#xD;
          5. Age minimum 16 years with no upper age limit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Eligibility for an human leukocyte antigens (HLA)-matched sibling donor transplant for&#xD;
             SAA patients&#xD;
&#xD;
          2. Prior therapy with ATG or CSA&#xD;
&#xD;
          3. Haematopoeitic growth factors more than 4 weeks before study enrolment&#xD;
&#xD;
          4. Diagnosis of Fanconi anaemia, dyskeratosis congenita or congenital bone marrow failure&#xD;
             syndrome&#xD;
&#xD;
          5. Evidence of myelodysplastic disease&#xD;
&#xD;
          6. Paroxysmal nocturnal haemoglobinuria with evidence of significant haemolysis, history&#xD;
             of Paroxysmal Nocturnal Hemoglobinuria (PNH) associated thrombosis or a PNH clone &gt;50%&#xD;
             by flow cytometry&#xD;
&#xD;
          7. Diagnosis or previous history of carcinoma (except local cervical, basal cell,&#xD;
             squamous cells, or melanoma)&#xD;
&#xD;
          8. Subject is pregnant (e.g. positive Human Chorionic Gonadotropin (HCG) test) or is&#xD;
             breast feeding&#xD;
&#xD;
          9. Severe uncontrolled infection or unexplained fever &gt;38 degrees Celsius&#xD;
&#xD;
         10. Subjects who have hepatic, renal cardiac, metabolic or other concurrent diseases of&#xD;
             such severity that life expectancy is less than 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Marsh, Prof. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital St. Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum - Institut für klinische Transfusionsmedizin</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital &amp; Research Cnetre</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George's Hospital/ St George's University of London</name>
      <address>
        <city>London</city>
        <zip>Sw17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham Universitry Hospital Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Saudi Arabia</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ebmt.org</url>
    <description>Sponsor's website</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/22544699/</url>
    <description>Publication</description>
  </link>
  <results_reference>
    <citation>Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, Killick SB, Warren AJ, Foukaneli T, Aljurf M, Al-Zahrani HA, Höchsmann B, Schafhausen P, Roth A, Franzke A, Brummendorf TH, Dufour C, Oneto R, Sedgwick P, Barrois A, Kordasti S, Elebute MO, Mufti GJ, Socie G; European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood. 2012 Jun 7;119(23):5391-6. doi: 10.1182/blood-2012-02-407684. Epub 2012 Apr 27. Erratum in: Blood. 2013 Jun 20;121(25):5104. Höchsmann, Britta [added].</citation>
    <PMID>22544699</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 9, 2007</study_first_submitted>
  <study_first_submitted_qc>May 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2007</study_first_posted>
  <results_first_submitted>December 21, 2020</results_first_submitted>
  <results_first_submitted_qc>September 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 18, 2021</results_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thymoglobuline</keyword>
  <keyword>Rabbit ATG</keyword>
  <keyword>Ciclosporin</keyword>
  <keyword>Aplastic Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>14 sites in 6 countries were open to include patients; in the end 10 sites entered all 35 patients. First Patient In (FPI) 04-Aug-2008, Last Patient In (LPI) 30-Sep-2010</recruitment_details>
      <pre_assignment_details>Naive aplastic anaemia patients</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm</title>
          <description>Antithymocyte globuline with cyclosporin in first line treatment of patients with acquired severe aplastic anaemia and patients with non-severe aplastic anaemia who are transfusion dependent; the results were compared with historical controls from the European Group for Blood and Marrow Transplantation (EBMT) database. Patients were matched for age and disease status (NSAA, SAA, VSAA)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35">35 registered patients received the full 5-day Rabbit Antithymocyte Globuline (RATG) treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm</title>
          <description>Antithymocyte globuline with cyclosporin in first line treatment of patients with acquired severe aplastic anaemia and patients with non-severe aplastic anaemia who are transfusion dependent; the results were compared with historical controls from the EBMT database. Patients were matched for age and disease status (NSAA, SAA, VSAA)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Response to Rabbit Antithymocyte Globuline (Thymoglobuline)</title>
        <description>Complet Response (CR) defined as:&#xD;
Haemoglobin normal for age and gender, neutrophils &gt; 1.5 x 10E9/l, platelets &gt; 150 x 10E9/l.&#xD;
Partial Response (PR) defined as:&#xD;
transfusion independence (if previously dependent) or&#xD;
doubling or normalisation of at least one cell line or&#xD;
increase of baseline haemoglobin of &gt; 3 g/dl (if initially &lt;6) + neutrophils of &gt; 0.5 x 10E9/l + platelets of &gt; 20 x 10E9/l (if initially &lt; 20)&#xD;
No Response (MR) is defined as: worse or not meeting criteria above</description>
        <time_frame>at 6months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Antithymocyte globuline with cyclosporin in first line treatment of patients with acquired severe aplastic anaemia and patients with non-severe aplastic anaemia who are transfusion dependent&#xD;
rabbit antithymocyte globulin: 1.5 vials/10kg daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response to Rabbit Antithymocyte Globuline (Thymoglobuline)</title>
          <description>Complet Response (CR) defined as:&#xD;
Haemoglobin normal for age and gender, neutrophils &gt; 1.5 x 10E9/l, platelets &gt; 150 x 10E9/l.&#xD;
Partial Response (PR) defined as:&#xD;
transfusion independence (if previously dependent) or&#xD;
doubling or normalisation of at least one cell line or&#xD;
increase of baseline haemoglobin of &gt; 3 g/dl (if initially &lt;6) + neutrophils of &gt; 0.5 x 10E9/l + platelets of &gt; 20 x 10E9/l (if initially &lt; 20)&#xD;
No Response (MR) is defined as: worse or not meeting criteria above</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>CR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Transplanted</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Dead</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Failure Free and Overall Survival of Participants to Rabbit Antithymocyte Globuline (Thymoglobuline)</title>
        <description>Failure free survival is defined as a failure of the protocol: no achievement of response, relapse, disease progression requiring a second course of immune suppressive therapy (IST) or a stem cell transplant, death, or later clonal disorders such as PNH, MDS and AML.</description>
        <time_frame>at 2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental: Treament Arm</title>
          <description>Antithymocyte globuline with cyclosporin in first line treatment of patients with acquired severe aplastic anaemia and patients with non-severe aplastic anaemia who are transfusion dependent</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vasovagal Episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatic endocrine, glucose intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pyrexia with rigours</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Unrelated Donor Stem Cell Transplant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction / Hypersensitivy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Serum Sickness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial Infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Blood-reactivation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Coccy geal fistula abscessed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Colonisation in Staphylococcus aures methicillin resistant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Facial Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Klebsiella Septicaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hickmann Line Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Norovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT levels</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyper Bilirubinimia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Clonal Malignancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral Basal Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Participating PIs can not publish on the patients they have included in this prospective trial before the results of the trial have been published in a peer-reviewed journal.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Judith Marsh</name_or_title>
      <organization>European Group for Blood and Marrow Transplantation</organization>
      <phone>+31 (0)71 5265005</phone>
      <email>a.j.barrois@lumc.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

